Evaluating the therapeutic efficacy of SKYCLARYS: a promising FDA-approved drug for Friedreich ataxia treatment
Usaid Ahmed(Dow University of Health Sciences), Aymar Akilimali(Roslin Institute), Aqeel Muhammad(Dow University of Health Sciences), Rumaisa Riaz(Dow University of Health Sciences), Laiba Afaq(Dow University of Health Sciences)
Cited by 1
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29
Barriers Encountered Toward Pursuing a Neurosurgical Career: A Cross-Sectional Study Among Medical Students, Interns, and Junior Doctors in Africa
|World Neurosurgery|2022|26
The unmet need of organ transplantation in Africa
|International Journal of Surgery|2023|21